Experience with gynestril in the treatment of patients with uterine myoma


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Article describes the evaluation of efficiency and tolerability of long-term gynestril therapy of uterine myoma. The efficiency and safety of the therapy were evaluated in 78 of the 86 patients included in the study. The clinical analysis of therapeutic effectiveness indicated that 83.3 of the patients achieved the maximal reduction in the sizes of leiomyomatous nodules. The symptoms of the disease could be controlled in 92% of the cases. The majority of the patients reported amenorrhea, hemoglobin recovery, and reduced pain. The side effects of treatment were observed in 8% of the patients. Patients were operated on if the therapy was ineffective or showed significant adverse reactions. The conclusion was made, that gynestril is highly effective, safe, and promising in the medical treatment of reproductive-aged and premenopausal patients with uterine myoma.

Full Text

Restricted Access

About the authors

Sergey A. Levakov

Institute of Advanced Training, Federal Biomedical Agency of Russia

Email: levakoff@yandex.ru
PhD, MD, Department of Obstetrics and Gynecology

Anna G. Kedrova

Institute of Advanced Training, Federal Biomedical Agency of Russia

Email: kedrova.anna@gmail.com
PhD, MD, Department of Obstetrics and Gynecology

Olga E. Nechaeva

Institute of Advanced Training, Federal Biomedical Agency of Russia

department of functional diagnostic and sonography

Nikita S. Vanke

Institute of Advanced Training, Federal Biomedical Agency of Russia

Email: wanke@rambler.ru
associate professor, Department of Obstetrics and Gynecology

Natalia N. Chelnokova

Medical Sanitary Unit One Hundred Seventy, Federal Biomedical Agency of Russia

Email: msdl70@extern.rsce.ru
Chief of the Gynecology department

Svetlana E. Levakova

Branch Two, City Polyclinic One Hundred Nine, Moscow Healthcare Department

Department of Obstetrics and Gynecology

References

  1. Okolo S. Incidence, aetiology and epidemiology of uterine fibroids. Best Pract. Res. Clin. Obstet. Gynaecol. 2008; 22: 571-88.
  2. Леваков С.А., Кедрова А.Г., Ванке Н.С. Современный взгляд на комплексное лечение больных миомой матки. Клиническая практика. 2010; 3: 15-9. [Levakov S.A., Kedrova A.G., Vanke N.S. The modern view of the complex treatment of patients with uterine myoma. Klinicheskaya praktika. 2010; 3: 15-9. (In Russian)]
  3. Flynn M., Jamison M., Datta S., Myers E. Health care resource use for uterine fibroid tumors in the United States. Am. J. Obstet. Gynecol. 2006; 195 (4): 955-64.
  4. Zhang Q., Ubago J., Li L., Guo H., Liu Y., Qiang W. et al. Molecular analyses of 6 different types of uterine smooth muscle tumors: Emphasis in atypical leiomyoma. Cancer. 2014; 120 (20): 3165-77. doi: 10.1002/cncr.28900
  5. Ищенко А.И., Ботвин М.А., Ланчинский В.И. Миома матки. Этиология, патогенез, диагностика, лечение. М.: Видар-М; 2010: 32-4. [Ishchenko A.I., Botvin M.A., Lanchinskij V.I. Uterine fibroids. Etiology, pathogenesis, diagnosis, treatment. M.: Vidar-M; 2010: 32-4. (In Russian)]
  6. Radosa M.P., Owsianowski Z., Mothes A., Weisheit A., Vorwergk J., Asskaryar F.A. et al. Long-term risk of fibroid recurrence after laparoscopic myomectomy. Eur. J. Obstet. Gynecol. Reprod. Biol. 2014; 180: 35-9.
  7. Freed M.M., Spies J.B. Uterine artery embolization for fibroids: a review of current outcomes. Semin. Reprod. Med. 2010; 28: 235-41.
  8. Bifulco G., Miele C., Pellicano M., Trencia A., Ferraioli M., Paturzo F. et al. Molecular mechanisms involved in GnRH analogue-related apoptosis for uterine leiomyomas. Mol. Hum. Reprod. 2004; 10: 43-8.
  9. Ke L.Q., Yang K., Li J., Li C.M. Danazol for uterine fibroids. Cochrane Database Syst. Rev. 2009; (3): CD007692.
  10. Ying Z., Weiyuan Z. Dual actions of progesterone on uterine leiomyoma correlate with the ratio of progesterone receptor A:B. Gynecol. Endocrinol. 2009; 25 (8): 520-3.
  11. Ishikawa H., Kazutomo Ishi, Serna V.A. Progesterone is essential for maintenance and growth of uterine leiomyomas. Endocrinology. 2010; 151 (6): 2433-42
  12. Lamminen S., Rantala I., Helin H., Rorarius M., Tuimala R. Proliferative activity of human uterine leiomyoma cells as measured by automatic image analysis. Gynecol. Obstet. Invest. 1992; 34 (2): 111-4.
  13. Kawaguchi K., Fujii S., Konishi I., Nanbu Y., Nonogaki H., Mori T. Mitotic activity in uterine leiomyomas during the menstrual cycle. Am. J. Obstet. Gynecol. 1989; 160 (3): 637-41.
  14. Cutini P.H., Massheimer V.L. Role of progesterone on the regulation of vascular muscle cells proliferation, migration and apoptosis. Steroids. 2010; 75 (4-5): 355-61.
  15. Tiltman A.J. The effect of progestins on the mitotic activity of uterine fibromyomas. Int. J. Gynecol. Pathol. 1985; 4: 89-96.
  16. Engman M., Granberg S., Williams A.R., Meng C.X., Lalitkumar P.G., Gemzell-Danielsson K. Mifepristone for treatment of uterine leiomyoma. A prospective randomized placebo controlled trial. Hum. Reprod. 2009; 24 (8): 1870-9.
  17. Eisinger S.H., Bonfiglio T., Fiscella K., Meldrum S., Guzick D.S. Twelve month safety and efficacy of low-dose mifepristone for uterine myomas. J. Minim. Invasive Gynecol. 2005; 12 (3): 227-33.
  18. Fiscella K., Eisinger S.H., Meldrum S., Feng C., Fisher S.G., Guzick D.S. Effect of mifepristone for symptomatic leiomyomata on quality of life and uterine size: a randomized controlled trial. Obstet. Gynecol. 2006; 108 (6): 1381-7.
  19. Kim J.J., Sefton E.C. The role of progesterone signaling in the pathogenesis of uterine leiomyoma. Mol. Cell. Endocrinol. 2012; 358 (2): 223-31.
  20. Steinauer J., Pritts E. A., Jackson R., Jacoby A.F. Systematic review of mifepristone for the treatment of uterine leiomyomas. Obstet. Gynecol. 2004; 103 (6): 1331-6.
  21. Engman M., Skoog L., Söderqvist G., Gemzell-Danielsson K. The effect of mifepristone on breast cell proliferation in premenopausal women evaluated through fine needle aspiration cytology. Hum. Reprod. 2008; 23 (9): 2072-9.
  22. Baird D.T., Brown A., Critchley H.O., Williams A.R., Lin S., Cheng L. Effect of long-term treatment with low-dose mifepristone on the endometrium. Hum. Reprod. 2003; 18 (1): 6168-71.
  23. Lalitkumar P.G., Lalitkumar S., Meng C.X., Stavreus-Evers A., Hambiliki F., Bentin-Ley U., Gemzell-Danielsson K. Mifepristone, but not levonorgestrel, inhibits human blastocyst attachment to an in vitro endometrial threedimensional cell culture model. Hum. Reprod. 2007; 22 (11): 3031-7.
  24. Baird D.T., Brown A., Cheng L., Critchley H.O., Lin S., Narvekar N., Williams A.R. Mifepristone: a novel estrogen-free daily contraceptive pill. Steroids. 2003; 68 (10-13): 1099-105.
  25. Carboneil J.L., Acosta R., Pérez Y., Garcés R., Sánchez C., Tomasi G. Treatment of uterine myoma with 2.5 or 5 mg mifepristone daily during 3 months with 9 months posttreatment followup: randomized clinical trial. Obstet. Gynecol. 2013; 2013: 649030.
  26. Чекалова М.А., Кузнецов В.В., Захарова Т.И. Ультразвуковая диагностика лейомиом и сарком матки. Опухоли женской репродуктивной системы. 2008; 3: 62-6. [Chekalova M.A., Kuznecov V.V., Zaharova T.I. Ultrasound diagnosis of uterine leiomyomas and sarcomas. Opuholi zhenskoj reproduktivnoj sistemy. 2008; 3: 62-6. (In Russian)]
  27. Seth S., Goel N., Singh E., Mathur A.S., Gupta G. Effect of mifepristone 25mg in treatment of uterine myoma in perimenopausal woman. J. Midlife Health. 2013; 4 (1): 22-6.
  28. Стрижаков А.Н., Давыдов А.И., Пашков В.М., Лебедев В.А. Доброкачественные заболевания матки. М.: ГЭОТАР-Медиа; 2014. [Strizhakov A.N., Davydov A.I., Pashkov V.M., Lebedev V.A. Benign disease of the uterus. M.: GEHOTAR-Media; 2014. (In Russian)]
  29. Narvekar N., Cameron S., Critchley H.O., Lin S., Cheng L., Baird D.T. Low-dose mifepristone inhibits endometrial proliferation and upregulates androgen receptor. J. Clin. Endocrinol. Metab. 2004; 89 (5): 2491-7.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2014 Bionika Media

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies